Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!

Single Use Manufacturing & the Impact on Process, Facility Design & Procurement

  • Posted by jwillard
  • On April 3, 2017
Single use technology opens up a world of possibilities never considered before for biotech/pharma manufacturing but also brings with it a host of new challenges. As companies move from simple application of single use systems like bags (for buffer storage) to more complex single use systems and even entire single use facilities, the potential impact […]
Read More
 
 Featured Image

Making the Leap from Student to Industry Professional: Introducing the YPC…

  • Posted by Chris Ciampa
  • On March 31, 2017
The Young Professionals Committee (YPC) would like to introduce ourselves by showcasing each of the current committee members, telling you a little bit about ourselves and the paths our careers have taken.  To start, I have been the chair of the YPC for 2-3 years.  I work at Thermo Fisher Scientific, which is a supplier […]
Read More
 

Amgen in Thousand Oaks, CA to Lay Off, Relocate 500 Employees, Some to MA

  • Posted by jwillard
  • On March 30, 2017
The Pacific Coast Business Times is reporting that on March 22, Amgen notified nearly 500 employees at their Thousand Oaks facility that they will be re-assigned, relocated, or laid off over the next year and a half. The reassigned employees will be transferred to a new facility in Tampa Bay or to R&D in Cambridge, […]
Read More
 

Flexion Stock Soars on Report of Sanofi Takeover

  • Posted by Janet Tice
  • On March 30, 2017
As reported by Robert Weisman in The Boston Globe, following a report that Burlington-based Flexion Therapeutics is negotiating a sale to French drug giant Sanofi, Flexion shares rose more than 33 percent. Spokeswomen for Sanofi and Flexion — which has a promising knee pain drug up before US regulators — declined to comment. The purchase […]
Read More
 

EMD Serono Wins FDA Approval for Drug to Treat Skin Cancer

  • Posted by Janet Tice
  • On March 30, 2017
The FDA has granted accelerated approval to Bavencio (avelumab) for the treatment of metastatic Merkel cell carcinoma (MCC). This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer, and EMD Serono’s first cancer drug launch. The drug has been approved for adults and pediatric patients 12 years and older, […]
Read More
 

Biogen Wins Patent Ruling for $4 Billion MS Treatment

  • Posted by Janet Tice
  • On March 30, 2017
As reported by Robert Weisman in The Boston Globe, Biogen’s patent on its top-selling multiple sclerosis treatment, Tecfidera, was upheld by a legal ruling in which the U.S. Patent Trial and Appeal Board rejected a challenge by Texas hedge fund manager Kyle Bass. Bass has been working for years to invalidate key intellectual property rights […]
Read More
 
 Featured Image

Is Continuous Manufacturing in Your Future?

  • Posted by Dan Pratt
  • On March 29, 2017
Is continuous manufacturing in your future? After all, the technology to enable continuous manufacturing of biopharmaceuticals is rapidly being developed. After attending the Chapter’s educational program at Takeda Pharmaceuticals on March 16, my conclusion is that continuous manufacturing is definitely in our future but, as with past transformations in technology, adoption by industry will be […]
Read More
 

Arrakis Therapeutics to Target RNA with Small-Molecule Medicines

  • Posted by Janet Tice
  • On March 23, 2017
Waltham-based Arrakis Therapeutics has completed a $38 million Series A financing led by Canaan Partners with participation by Pfizer, Celgene, and biotech industry leader Henri Termeer, among others. Arrakis was founded with a vision to create a proprietary, transformational discovery platform that identifies small-molecule drugs that act directly on disease-causing RNA.  The company was established […]
Read More
 

Vertex to Acquire Concert Pharmaceuticals’ Drug for Treatment of Cystic Fibrosis

  • Posted by Janet Tice
  • On March 23, 2017
Vertex Pharmaceuticals has agreed to acquire CTP-656 from Lexington-based Concert Pharmaceuticals. CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to assist in treating the underlying cause of cystic fibrosis (CF). As part of the agreement, Vertex will pay Concert $160 million in cash for worldwide development and commercialization […]
Read More
 

WPI’s BETC Offers Free Undergrad Biotech Training Programs

  • Posted by kpicard
  • On March 16, 2017
The Biomanufacturing Education and Training Center (BETC) at Worcester Polytechnic Institute is hosting three student training sessions in March and April as part of our Undergraduate Student Training Program. The goal is to provide undergraduate students with hands-on learning opportunities that can be beneficial as they prepare for a career in the biotech industry. These […]
Read More